AtriCure Newsroom

Baiyang Medical (301015.SZ): Currently has established a presence in the high-end medical instrument field with Atricure's atrial fibrillation treatment devices, and products like the full magnetic suspension artificial heart from Tongxin Medical.

HealthTimes reported on November 28th that Baiyang Pharmaceuticals (301015.SZ) stated in a recent investor relations event that the company has currently laid out Atricure's atrial fibrillation treatment equipment, Syncardia's fully magnetically levitated artificial heart, Medisense's ultrasound-guided electromagnetic positioning puncture device, and Wecare's home ECG monitor in the high-end medical instruments field; recently, the company has obtained the exclusive commercial operation rights of ZAP Surgical's ZAP-X Mars Rover radiotherapy surgical robot in mainland China and Hong Kong-Macao region.

Gelonghui FinanceNov 28 04:29 ET

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

BusinesswireNov 20 08:00 ET

The Market Lifts AtriCure, Inc. (NASDAQ:ATRC) Shares 28% But It Can Do More

Simply Wall StNov 6 06:00 ET

US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results

Yahoo FinanceNov 1 07:51 ET

Are Investors Undervaluing AtriCure, Inc. (NASDAQ:ATRC) By 29%?

Simply Wall StOct 31 08:47 ET

AtriCure | 10-Q: Q3 2024 Earnings Report

SECOct 30 11:52 ET · Announcements

AtriCure Is Maintained at Overweight by JP Morgan

Dow JonesOct 30 11:30 ET · Ratings

Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday

BenzingaOct 30 11:26 ET

AtriCure Up Over 23%, on Pace for Largest Percent Increase Since June 2009 -- Data Talk

Dow JonesOct 30 11:13 ET

Q3 2024 AtriCure Inc Earnings Call

Yahoo FinanceOct 30 10:19 ET

AtriCure Plans a Surgical Pulsed Field Ablation Play

MassDeviceOct 30 10:06 ET

UBS Maintains Buy on AtriCure, Raises Price Target to $40

BenzingaOct 30 09:34 ET · Ratings

A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $36 to $60

Moomoo NewsOct 30 09:00 ET · Ratings

CalciMedica CALC Phase 2b Data; AtriCure ATRC Earnings

BioPharmCatalystOct 30 08:20 ET

AtriCure Analyst Ratings

BenzingaOct 30 06:55 ET · Ratings

Express News | AtriCure Inc : Canaccord Genuity Raises Target Price to $53 From $49

ReutersOct 30 03:02 ET

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript Summary

moomoo AIOct 30 00:29 ET · Conference Call

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsOct 29 23:53 ET

AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Yahoo FinanceOct 29 19:00 ET

AtriCure Gains 10%+ After Hours on Q3 Sales Beat and Narrower-Than-Expected Loss

BenzingaOct 29 17:05 ET